Zenflow announces Spring System data for benign prostatic hyperplasia
The studies, which included 72 participants, utilised IPSS and IPSS-QOL to measure symptom improvement.
Medical device company Zenflow has reported that its Spring System demonstrated durable benefits three years post-placement for individuals with benign prostatic hyperplasia (BPH) in the ZEST pilot studies. According to the company, the device is setting up a new category of treatment called first-line interventional therapy (FIT), aiming to offer minimally invasive treatments with safety advantages and reversibility akin to medication. These studies showed that at the 36-month mark, individuals who received treatment with the Zenflow Spring exhibited a 46% improvement in their International Prostate Symptom Score (IPSS) compared to baseline.
